PharmiWeb

Ono Pharma Announces New Drug Discovery Collaboration with Congruence Therapeutics in the Priority Areas of Neurology and Immunology

Beginning a new drug discovery collaboration using Congruence’s globally recognized Revenir™ platform for the creation of small molecule modulatorsExpanded collaboration into Ono’s other priority ...
PharmiWeb

3T Biosciences Appoints Rebeca Villarreal-Barragan, MBA, as Head of Clinical Operations

Villarreal-Barragan brings global experience delivering first-in-human and complex biomarker-driven oncology trials for ...
PharmiWeb

Faron Pharmaceuticals Ltd: Results of the Extraordinary General Meeting

TURKU, FI / ACCESS Newswire / March 2, 2026 / Faron Pharmaceuticals Ltd (HEL:FARON)(LSE:FARN), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, ...
PharmiWeb

Nutraceuticals Market Growth Study, Future Trends, Demands, and Top Players Data by Forecast to 2030

The global nutraceuticals market, valued at approximately USD 416 billion in 2026, is projected to grow at a CAGR of around 9 ...
PharmiWeb

Heritage Global Partners Opens New San Diego Headquarters, Doubling Capacity to Support Next Phase of Growth

Heritage Global Partners (“HGP”), a subsidiary of Heritage Global Inc. (NASDAQ: HGBL) and a worldwide leader in asset advisory and auction services, today announced the official opening of its new ...
PharmiWeb

IQVIA CFO to Speak at Barclays 28th Annual Global Healthcare Conference

IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, ...
PharmiWeb

IQVIA CEO to Speak at Leerink Partners 2026 Global Healthcare Conference

IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, ...
PharmiWeb

Cure Rare Disease and LGMD2L Foundation Announce Multi-Year Partnership to Develop Gene Therapy for Anoctamin 5-Related Disease

Cure Rare Disease (CRD), a non-profit biotechnology organization, today announced a landmark partnership with the LGMD2L Foundation. This collaboration is backed by a generous commitment of $7.65 ...
PharmiWeb

The Leadership Development Group and Northeast Georgia Health System Mark Six Years of Adaptive Leadership Development - Evolving from Physicians to Dyads to Apps

Demonstrating the power of adaptive design, NGHS and TLD Group celebrate six years of leadership growth across the health system. NEW YORK CITY, NY / ACCESS Newswire / March 2, 2026 / The Leadership ...
PharmiWeb

Justera Announces Definitive Agreement to Sell Port North Extracts Inc. and Resignations

TORONTO, ON / ACCESS Newswire / March 2, 2026 / Justera Health Ltd. (CSE:VTAL)(OTC PINK:SCRSF) ("Justera" or the "Company") announces that it signed a definitive share and asset purchase agreement ...
PharmiWeb

Genentech's Fenebrutinib Confirms Its Potential as First and Only BTK Inhibitor for Relapsing and Primary Progressive MS in Third Positive Phase III Study (FENhance 1)

FENhance 1 met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses by 51% compared to teriflunomide in relapsing multiple sclerosis (RMS), consistent with ...
PharmiWeb

Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy ...

Rusfertide Demonstrated Significant Improvements in Hematocrit Control, Phlebotomy Reduction and Patient Reported Outcomes for Patients with Polycythemia Vera in a Pivotal StudySubmission Primarily ...